Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Very strong names appointed

<< Previous

Bullboard Posts

Next >>

Post by ForexWhaleon Oct 23, 2018 12:07pm

196 Views

Post# 28856745

Very strong names appointed

Both the experts are well respected and positioned. They must have seen Phase 1 numbers.

Professor David W. Denning is from UK and has a global outlook on infectious diseases. Funding must be in place and just finalzing. Read more here

https://www.aspergillus.org.uk/content/professor-david-w-denning-mb-bs-frcp-frcpath-dch-fmedsci-0

I am more positive than ever this is getting funded real soon. All the best whoever is holding and not getting impatient.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks